Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA's Transparency Initiative Enters The "What Is The Right Thing To Do" Phase: An Interview With Principal Deputy Commissioner Sharfstein

Executive Summary

In June, FDA launched an internal Transparency Task Force to evaluate how to make the agency's decision-making process more accessible to the public. The agency held two public meetings and solicited comments from the public; the docket closed Nov. 6. FDA Principal Deputy Commissioner Joshua Sharfstein, who chairs the task force, spoke to "The Pink Sheet" about its initial findings

You may also be interested in...



FDA Transparency Initiative Sees No Clear Path To Releasing Documents, Woodcock Indicates

FDA is finding the possible release of its voluminous documents one of the more challenging aspects of the effort to make its operations and decisions more open to the public, and the challenges are both in policies and resources, FDA's Janet Woodcock says

FDA Transparency Initiative Sees No Clear Path To Releasing Documents, Woodcock Indicates

FDA is finding the possible release of its voluminous documents one of the more challenging aspects of the effort to make its operations and decisions more open to the public, and the challenges are both in policies and resources, FDA's Janet Woodcock says

FDA Transparency Initiative Sees No Clear Path To Releasing Documents, Woodcock Indicates

Requirements to redact proprietary information from documents, make them accessible to the disabled, and other challenges would greatly tax FDA staff, FDA's Janet Woodcock says.

Related Content

Topics

UsernamePublicRestriction

Register

PS051709

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel